Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

od van der Horst, Hilma J., Gelderloos, Anne T., Chamuleau, Martine E. D., Breij, Esther C. W., Zweegman, Sonja, Nijhof, Inger S., Overdijk, Marije B., Mutis, Tuna
Wydane w Blood Adv (2021)

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

od Roit, Fabio Da, Engelberts, Patrick J., Taylor, Ronald P., Breij, Esther C.W., Gritti, Giuseppe, Rambaldi, Alessandro, Introna, Martino, Parren, Paul W.H.I., Beurskens, Frank J., Golay, Josée
Wydane w Haematologica (2015)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

od Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI
Wydane w MAbs (2015)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

od van der Horst, Hilma J., Oostindie, Simone C., Cillessen, Saskia. A. G. M., Gelderloos, Anne T., Overdijk, Marije B., Nijhof, Inger. S., Zweegman, Sonja, Chamuleau, Martine E. D., Breij, Esther C. W., Mutis, Tuna
Wydane w Hemasphere (2020)

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer

od Koopman, Louise A., Terp, Mikkel G., Zom, Gijs G., Janmaat, Maarten L., Jacobsen, Kirstine, Gresnigt-van den Heuvel, Elke, Brandhorst, Marcel, Forssmann, Ulf, de Bree, Freddy, Pencheva, Nora, Lingnau, Andreas, Zipeto, Maria A., Parren, Paul W.H.I, Breij, Esther C.W., Ditzel, Henrik J.
Wydane w JCI Insight (2019)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

od van der Horst, Hilma J., de Jonge, A. Vera, Hiemstra, Ida H., Gelderloos, Anne T., Berry, Daniella R. A. I., Hijmering, Nathalie J., van Essen, Hendrik F., de Jong, Daphne, Chamuleau, Martine E. D., Zweegman, Sonja, Breij, Esther C. W., Roemer, Margaretha G. M., Mutis, Tuna
Wydane w Blood Cancer J (2021)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

od Engelberts, Patrick J., Hiemstra, Ida H., de Jong, Bart, Schuurhuis, Danita H., Meesters, Joyce, Beltran Hernandez, Irati, Oostindie, Simone C., Neijssen, Joost, van den Brink, Edward N., Horbach, G. Jean, Verploegen, Sandra, Labrijn, Aran F., Salcedo, Theodora, Schuurman, Janine, Parren, Paul W.H.I, Breij, Esther C.W.
Wydane w EBioMedicine (2020)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

od Oostindie, Simone C., van der Horst, Hilma J., Lindorfer, Margaret A., Cook, Erika M., Tupitza, Jillian C., Zent, Clive S., Burack, Richard, VanDerMeid, Karl R., Strumane, Kristin, Chamuleau, Martine E. D., Mutis, Tuna, de Jong, Rob N., Schuurman, Janine, Breij, Esther C. W., Beurskens, Frank J., Parren, Paul W. H. I., Taylor, Ronald P.
Wydane w Haematologica (2019)

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

od Oostindie, Simone C., van der Horst, Hilma J., Kil, Laurens P., Strumane, Kristin, Overdijk, Marije B., van den Brink, Edward N., van den Brakel, Jeroen H. N., Rademaker, Hendrik J., van Kessel, Berris, van den Noort, Juliette, Chamuleau, Martine E. D., Mutis, Tuna, Lindorfer, Margaret A., Taylor, Ronald P., Schuurman, Janine, Parren, Paul W. H. I., Beurskens, Frank J., Breij, Esther C. W.
Wydane w Blood Cancer J (2020)